

Reference

I-13

1. ClinicalTrials.gov. U.S. National Institutes of Health. A phase III study of TMC435 in Genotype I, hepatitis C infected participants who failed to respond to previous IFN based therapy. ClinicalTrials.gov Identifier: NCT01288209.
2. American Association for the Study of Liver Disease (AASLD). Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases.
3. Telaprevir. DRUGDEX System. New York: Thomson Reuters; 2012. Last Modified July 30, 2013. Telaprevir. Clinical Pharmacology. Tampa, FL: Gold Standard, Inc. 2012.
4. Boceprevir. DRUGDEX System. New York: Thomson Reuters; 2012. Last Modified July 22, 2013.
5. Tatsuo K, Nakamoto S, Nishino T, et al. Peginterferon alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy. *Int J Med Sci.* 2013;10(1):43-49.
6. Salvatierra K, Fareleski S, Forcada A, et al. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. *World J Virol.* 2013 February 12;2(1):6-15.
7. Incivek (telaprevir) prescribing information. Vertex Pharmaceuticals, Inc. Cambridge, MA. April 2013.
8. Victrelis (boceprevir) prescribing information. Merck & Co., Inc. Whitehouse Station, NJ. February 2013.
9. Sovaldi (sofosbuvir) prescribing information. Gilead Sciences. December 2013.
10. Sofosbuvir. DRUGDEX System. New York: Thomson Reuters; 2013. Last Modified January 27, 2014.
11. Olysio (simeprevir) prescribing information. Janssen Therapeutics, Inc. Titusville, NJ. November 2013.
12. Pegasys (peginterferon alfa -2a) prescribing information. Genentech. Revised 07/2013.
13. Lawitz E, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *New England Journal of Medicine.* 2013;368.20:1878-1887.
14. Jacobson IM, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *New England Journal of Medicine.* 2013;368.20:1867-1877.
15. Tefferi A. Prognosis and treatment of polycythemia vera. *UpToDate.* 2014
16. Sanjiv C, Muir A. Treatment regimens for chronic hepatitis C virus genotype 1. *UpToDate.* 2014 March.
17. Recommendations for Testing, Managing, and Treating Hepatitis C. AASLD and IDSA guidelines.

18. NCCN Drugs & Biologics Compendium ® Interferon alfa-2b, recombinant .
19. Afdhal N, Reddy R, Nelson D, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014;370:1483-1493.